Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714514 · ClinicalTrials.gov registry record
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
A clinical trial of Kidney Transplantation in Highly Sensitized Patients, sponsored by Hansa Biopharma AB.
- Active
- Registry status
- 64
- Enrollment target
- 14
- Study locations
NCT05714514: Active study of Kidney Transplantation in Highly Sensitized Patients, sponsored by Hansa Biopharma AB.
NCT05714514 is a study of Kidney Transplantation in Highly Sensitized Patients that is active but no longer recruiting, run by Hansa Biopharma AB. The registered enrollment target is 64 participants. The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714514, a study of Kidney Transplantation in Highly Sensitized Patients, is active but no longer recruiting, sponsored by Hansa Biopharma AB.
- ACTIVE NOT RECRUITING
- Registry status
- 64 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Conditions Studied
Interventions
- DRUG Imlifidase administered in the ConfIdeS study
- OTHER Best available treatment administered in the ConfIdeS study
Study Locations (14)
Illinois
- Northwestern University, Dept. General Surgery, Div. Transplantation - Chicago
- University of Chicago, Department of Surgery, Clinical Research Center - Chicago
New York
- New York University (NYU) Langone Transplant Institute, NYU Langone Health - New York
- Columbia University - New York
Texas
- Houston Methodist Hospital - Houston
- Methodist Hospital Specialty and Transplant - San Antonio
Alabama
- University of Alabama at Birmingham (UAB) Hospital - Birmingham
California
- Cedars-Sinai Medical Center - Los Angeles
Maryland
- John Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2029-12-31 |
What the registry record for NCT05714514 still lists
NCT05714514 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 1 condition, with Kidney Transplantation in Highly Sensitized Patients appearing as the primary indexed condition, and to 2 interventions - of which Imlifidase administered in the ConfIdeS study is the first listed.
NCT05714514 lists 14 locations in 11 states (Illinois, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT05714514 about?
NCT05714514 is a clinical study titled "Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys". The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, N...
What is the current status of trial NCT05714514?
This trial is currently active not recruiting. The enrollment target is 64 participants. The study started on 2023-04-21. Estimated completion is 2029-12-31.
What conditions does trial NCT05714514 study?
This clinical trial studies the following conditions: Kidney Transplantation in Highly Sensitized Patients.
What interventions are being tested in trial NCT05714514?
The interventions under investigation include: Imlifidase administered in the ConfIdeS study (DRUG), Best available treatment administered in the ConfIdeS study (OTHER).
Who is sponsoring clinical trial NCT05714514?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714514 being conducted?
This trial has 14 study locations across Alabama, California, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation in Highly Sensitized Patients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI